Effects of 13-cis-retinoic acid on melanoma patients
Author Information
Author(s): F Formelli, E Cavadini, L Mascheroni, F Belli, N Cascinelli
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
The study aims to evaluate the pharmacokinetics of 13-cis-retinoic acid and its effects on retinol plasma levels in melanoma patients.
Conclusion
The study found that 13-cis-retinoic acid treatment led to a temporary reduction in retinol plasma levels in melanoma patients.
Supporting Evidence
- Maximum 13-cis-retinoic acid blood concentrations occurred 4 hours after administration.
- Retinol plasma levels decreased by approximately 20% shortly after 13-cis-retinoic acid dosing.
- The pharmacokinetics of 13-cis-retinoic acid did not change after multiple doses.
Takeaway
This study looked at how a medicine called 13-cis-retinoic acid affects vitamin A levels in people with skin cancer.
Methodology
Patients were treated with either 20 mg or 40 mg of 13-cis-retinoic acid and their blood was sampled to measure drug and retinol levels.
Limitations
The study had a small sample size and variability in drug absorption among patients.
Participant Demographics
Patients were melanoma patients with regional node metastases who had undergone radical surgery.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website